# Mabel Ryder

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mabel-ryder/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,015 |
| Field | Thyroid Cancer Diagnosis and Treatment |
| h-index | 30 |
| i10-index | 49 |
| Last Known Institution | Mayo Clinic in Arizona |
| OpenAlex ID | https://openalex.org/A5070869307 |
| ORCID iD | 0000-0002-0520-6505 |
| Works | 167 |

## Researcher papers

- [Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/management-of-immunotherapy-related-toxicities-version-1-2019-nccn-clinical/)
- [Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for <i>BRAF, PIK3CA</i> , and <i>AKT1</i>](https://scholariq.org/papers/mutational-profile-of-advanced-primary-and-metastatic-radioactive-iodine/)
- [NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-management-of-immunotherapy-related-toxicities-version/)
- [Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution](https://scholariq.org/papers/endocrine-related-adverse-events-following-ipilimumab-in-patients-with-advanced/)
- [Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/management-of-immunotherapy-related-toxicities-version-1-2022-nccn-clinical/)
- [Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation](https://scholariq.org/papers/small-molecule-mapk-inhibitors-restore-radioiodine-incorporation-in-mouse/)
- [Relief of Feedback Inhibition of <i>HER3</i> Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in <i>BRAF</i> -Mutant Thyroid Carcinomas](https://scholariq.org/papers/relief-of-feedback-inhibition-of-i-her3-i-transcription-by-raf-and-mek/)
- [Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond](https://scholariq.org/papers/targeted-therapy-for-advanced-thyroid-cancer-kinase-inhibitors-and-beyond/)
- [Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms](https://scholariq.org/papers/pembrolizumab-induced-thyroiditis-comprehensive-clinical-review-and-insights/)
- [PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients](https://scholariq.org/papers/pd-l1-inhibitor-induced-thyroiditis-is-associated-with-better-overall-survival/)
- [Quantification of Initial Symptom Relief Following Ultrasound-Guided Radiofrequency Ablation of Benign Thyroid Nodules](https://scholariq.org/papers/quantification-of-initial-symptom-relief-following-ultrasound-guided/)

## Researcher topics

- [Thyroid Cancer Diagnosis and Treatment](https://scholariq.org/topics/thyroid-cancer-diagnosis-and-treatment/)
- [Thyroid Disorders and Treatments](https://scholariq.org/topics/thyroid-disorders-and-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Thyroid and Parathyroid Surgery](https://scholariq.org/topics/thyroid-and-parathyroid-surgery/)
- [Computational Drug Discovery Methods](https://scholariq.org/topics/computational-drug-discovery-methods/)

## Researcher university

- [Mayo Clinic in Arizona](https://scholariq.org/institutions/mayo-clinic-in-arizona/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.